HIF1A antibody (Internal Region)

Catalog No. ABIN350370

This anti-HIF1A antibody is a Rabbit Polyclonal antibody detecting HIF1A in WB and IHC. Suitable for Human.

Quick Overview for HIF1A antibody (Internal Region) (ABIN350370)

Target: HIF1A (Hypoxia Inducible Factor 1, alpha Subunit (Basic Helix-Loop-Helix Transcription Factor) (HIF1A))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HIF1A antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC)

Product Details anti-HIF1A Antibody

Binding Specificity: Internal Region

Purpose: Rabbit antibody to HIF1 alpha

Specificity: Specific for HIF1A.

Cross-Reactivity: Human

Cross-Reactivity (Details): Other species not yet tested.

Purification: IgG

Immunogen: A synthetic peptide from the internal region of human HIF1 alpha (HIF1A MOP1 Hypoxia-inducible factor 1 alpha) conjugated to an immunogenic carrier protein was used as the immunogen. The antigen shares 94% identity with rat and mouse sequences.

Isotype: IgG

Application Details

Application Notes: IHC WB. A concentration of 10-50,micro,g,ml is recommended. The optimal concentration should be determined by the end user. Not yet tested in other applications.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Reconstitute in 500 µl of sterile water. Centrifuge to remove any insoluble material.

Handling Advice: Avoid freeze and thaw cycles.

Storage: 4 °C,-20 °C

Storage Comment: Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.

Expiry Date: 12 months

Target Details for HIF1A

Target: HIF1A (Hypoxia Inducible Factor 1, alpha Subunit (Basic Helix-Loop-Helix Transcription Factor) (HIF1A))

Alternative Name: HIF1 alpha

Background: Function: Functions as a master transcriptional regulator of the adaptive response to hypoxia. Under hypoxic conditions activates the transcription of over 40 genes including erythropoietin glucose transporters glycolytic enzymes vascular endothelial growth factor and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. Plays an essential role in embryonic vascularization tumor angiogenesis and pathophysiology of ischemic disease. Binds to core DNA sequence 5'-[AG]CGTG-3' within the hypoxia response element (HRE) of target gene promoters. Activation requires recruitment of transcriptional coactivators such as CREBPB and EP300. Activity is enhanced by interaction with both NCOA1 or NCOA2. Interaction with redox regulatory protein APEX seems to activate CTAD and potentiates activation by NCOA1 and CREBBP. Subcellular location: Cytoplasm. Nucleus. Note: Cytoplasmic in normoxia nuclear translocation in response to hypoxia. Colocalizes with SUMO1 in the nucleus under hypoxia. Tissue specificity: Expressed in most tissues with highest levels in kidney and heart. Overexpressed in the majority of common human cancers and their metastases due to the presence of intratumoral hypoxia and as a result of mutations in genes encoding oncoproteins and tumor suppressors.

UniProt: Q16665

Pathways: Positive Regulation of Peptide Hormone Secretion, Regulation of Hormone Metabolic Process, Regulation of Hormone Biosynthetic Process, Cellular Response to Molecule of Bacterial Origin, Carbohydrate Homeostasis, Transition Metal Ion Homeostasis, Tube Formation, Regulation of Carbohydrate Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, VEGFR1 Specific Signals, Warburg Effect